ResMed Inc. (RMD) FY2027 Q1 Statement of Cash Flows

Published · Updated Source: Form 10-Q on SEC EDGAR filed (opens in a new tab)

Key Takeaways

  • Operating cash fell $34.90 M to $422.42 M, even as profit rose $69.88 M.
  • Share buybacks of $936.38 M dwarfed the $94.95 M in dividends and $250.00 M of debt repaid.
  • Cash after capital spending, $373.68 M, covered 36% of the $1.03 B paid out.
  • The share count fell 2.4% in a year, but the buyback cost $936.38 M in cash this quarter.
  • Inventories took $71.76 M of cash, and finished goods rose $72.08 M in the quarter.

The Unvarnished Truth

ResMed paid shareholders $1.03 B, 2.8 times its free cash.

ResMed's cash from operations, the money its everyday business brings in once its bills are paid, fell $34.90 M to $422.42 M, even as profit rose $69.88 M. That gap is the first alarm. The bigger one is what came next: ResMed paid out $1.03 B to its shareholders, a sum 2.8 times the $373.68 M it kept after spending on equipment. Cash from operations is the figure to watch, because it shows what the business produced in cash before any sale of assets.

Where did the money go? Purchases of treasury stock, the company's own shares, came to $936.38 M. Management ties the jump to buybacks, and it says the year-earlier figure was $150 million. A $450 million accelerated buyback agreement was paid in part from the MatrixCare sale, which the cash table books as $450.82 M of investing cash, not as operating cash. Debt is the other drain: ResMed repaid $250.00 M of its 3.24% senior notes, which were repaid in full on July 10, 2026.

Put together, ResMed kept $373.68 M after capital spending and sent $1.03 B to shareholders in one quarter, which is why its cash fell $458.49 M to $1.01 B. The filing says working capital drove the drop in operating cash, with inventory the biggest piece. The accelerated buyback still has to settle by December 29, 2026, which keeps the drain running into the next quarter. Will the finished goods sell through before the next buyback draws on the same cash pile?

2026-07-01 to 2026-09-30

Statement of Cash Flows

Swipe to see the full flow
ResMed Inc. cash flow reconciliation, Jul 1, 2026 through Sep 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Net income → Net cash from operating activities: $418,413,000.00Accounts receivable, net → Operating adjustments reconciliation: $64,839,000.00Accounts payable, accrued expenses, income taxes payable and other → Operating adjustments reconciliation: $62,761,000.00Depreciation and amortization → Operating adjustments reconciliation: $41,741,000.00Stock-based compensation costs → Operating adjustments reconciliation: $29,475,000.00Amortization of right-of-use assets → Operating adjustments reconciliation: $10,090,000.00Non-cash restructuring expenses → Operating adjustments reconciliation: $6,242,000.00Operating adjustments reconciliation → Net cash from operating activities: $4,009,000.00Operating adjustments reconciliation → Inventories: $71,764,000.00Operating adjustments reconciliation → Prepaid expenses, net deferred income taxes and other current assets: $69,988,000.00Operating adjustments reconciliation → (Gain) loss on divestment of subsidiaries: $61,784,000.00Operating adjustments reconciliation → (Gain) loss on equity investments: $5,719,000.00Operating adjustments reconciliation → (Gain) loss attributable to equity method investments: $1,884,000.00Proceeds from divestment of subsidiaries, net of cash divested → investing reconciliation: $450,820,000.00Proceeds (payments) on maturity of foreign currency contracts → investing reconciliation: $2,615,000.00investing reconciliation → Net cash from investing activities: $392,055,000.00investing reconciliation → Purchases of property, plant and equipment: $48,740,000.00investing reconciliation → Business acquisitions, net of cash acquired: $7,487,000.00investing reconciliation → Purchases of investments: $2,721,000.00investing reconciliation → Patent registration and acquisition costs: $2,432,000.00Net cash used in financing activities → financing reconciliation: $1,278,003,000.00Proceeds from issuance of common stock, net → financing reconciliation: $3,654,000.00financing reconciliation → Purchases of treasury stock: $936,378,000.00financing reconciliation → Repayment of borrowings: $250,000,000.00financing reconciliation → Dividends paid: $94,954,000.00financing reconciliation → Taxes paid related to net share settlement of equity awards: $325,000.00Exchange-rate effect → Cash sources and uses: $5,034,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $1,469,234,000.00Net cash from operating activities → Cash sources and uses: $422,422,000.00Net cash from investing activities → Cash sources and uses: $392,055,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $1,010,742,000.00Cash sources and uses → Net cash used in financing activities: $1,278,003,000.00Net income: $418,413,000.00Net income+$418.41 MDepreciation and amortization: $41,741,000.00Depreciation & amortization+$41.74 MAmortization of right-of-use assets: $10,090,000.00Operating lease amortization+$10.09 MStock-based compensation costs: $29,475,000.00Stock-based compensation+$29.48 M(Gain) loss attributable to equity method investments: -$1,884,000.00Equity-method results−$1.88 M(Gain) loss on equity investments: -$5,719,000.00Equity securities gain & loss−$5.72 MAccounts receivable, net: $64,839,000.00Accounts receivable+$64.84 MInventories: -$71,764,000.00Inventories−$71.76 MPrepaid expenses, net deferred income taxes and other current assets: -$69,988,000.00Prepaid & other assets−$69.99 MAccounts payable, accrued expenses, income taxes payable and other: $62,761,000.00Payables & accrued liabilities+$62.76 M(Gain) loss on divestment of subsidiaries: -$61,784,000.00Business sale gain & loss−$61.78 MNon-cash restructuring expenses: $6,242,000.00Non-cash restructuring expenses+$6.24 MNet cash from operating activities: $422,422,000.00Operating cash+$422.42 MOperating adjustments reconciliation: $215,148,000.00Proceeds from issuance of common stock, net: $3,654,000.00Common stock issued+$3.65 MTaxes paid related to net share settlement of equity awards: -$325,000.00Stock-award tax withholding−$325.00 KPurchases of treasury stock: -$936,378,000.00Common stock repurchases−$936.38 MRepayment of borrowings: -$250,000,000.00Long-term debt repaid−$250.00 MDividends paid: -$94,954,000.00Dividends paid−$94.95 MNet cash used in financing activities: -$1,278,003,000.00. Cash required to fund net payments.Financing cash−$1.28 Bfinancing reconciliation: $1,281,657,000.00Purchases of property, plant and equipment: -$48,740,000.00PP&E purchases−$48.74 MPatent registration and acquisition costs: -$2,432,000.00Patent registration and acquisition costs−$2.43 MBusiness acquisitions, net of cash acquired: -$7,487,000.00Acquisitions, net of cash−$7.49 MPurchases of investments: -$2,721,000.00Investment purchases−$2.72 MProceeds (payments) on maturity of foreign currency contracts: $2,615,000.00Derivatives, net+$2.62 MProceeds from divestment of subsidiaries, net of cash divested: $450,820,000.00Business sales, net of cash+$450.82 MNet cash from investing activities: $392,055,000.00Investing cash+$392.06 Minvesting reconciliation: $453,435,000.00Cash sources and uses: $2,288,745,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $1,469,234,000.00Beginning cash$1.47 BEnding cash: Cash, cash equivalents, and restricted cash: $1,010,742,000.00Ending cash$1.01 BExchange-rate effect: $5,034,000.00FX effect+$5.03 MCASH RECONCILIATIONOperatingflowsInvestingflowsFinancingflowsFree cash flow$373.68 MOperating cash − cash spent on PP&ECash flow / Net income1.01×Operating cash flow ÷ net incomeNet cash change−$458.49 MEnding cash − beginning cash
Chart details

ResMed Inc. cash flow reconciliation, Jul 1, 2026 through Sep 30, 2026

Cash flows for Jul 1, 2026 through Sep 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Jun 30, 2026. Ending cash: Sep 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Jun 30, 2026
1,469,234,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
422,422,000 US dollars. Net cash provided.
Net income
418,413,000 US dollars
Depreciation and amortization
41,741,000 US dollars
Amortization of right-of-use assets
10,090,000 US dollars
Stock-based compensation costs
29,475,000 US dollars
(Gain) loss attributable to equity method investments
negative 1,884,000 US dollars
(Gain) loss on equity investments
negative 5,719,000 US dollars
Accounts receivable, net
64,839,000 US dollars
Inventories
negative 71,764,000 US dollars
Prepaid expenses, net deferred income taxes and other current assets
negative 69,988,000 US dollars
Accounts payable, accrued expenses, income taxes payable and other
62,761,000 US dollars
(Gain) loss on divestment of subsidiaries
negative 61,784,000 US dollars
Non-cash restructuring expenses
6,242,000 US dollars
Investing activities
392,055,000 US dollars. Net cash provided.
Purchases of property, plant and equipment
negative 48,740,000 US dollars
Patent registration and acquisition costs
negative 2,432,000 US dollars
Business acquisitions, net of cash acquired
negative 7,487,000 US dollars
Purchases of investments
negative 2,721,000 US dollars
Proceeds (payments) on maturity of foreign currency contracts
2,615,000 US dollars
Proceeds from divestment of subsidiaries, net of cash divested
450,820,000 US dollars
Financing activities
negative 1,278,003,000 US dollars. Net cash used.
Proceeds from issuance of common stock, net
3,654,000 US dollars
Taxes paid related to net share settlement of equity awards
negative 325,000 US dollars
Purchases of treasury stock
negative 936,378,000 US dollars
Repayment of borrowings
negative 250,000,000 US dollars
Dividends paid
negative 94,954,000 US dollars
Operating adjustment reconciliation
215,148,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
1,281,657,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
453,435,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
5,034,000 US dollars
Ending cash on Sep 30, 2026
1,010,742,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
2,288,745,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
negative 458,492,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
1.01×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
Operating cash flow
422,422,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
48,740,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
373,682,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net income enters operating cash directly in the reconciliation. The adjustment junction contributes the remaining $4.01M after reconciling the other positive and negative adjustments. These connections depict an accounting reconciliation, not traced cash receipts.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 422,422,000 US dollars minus 48,740,000 US dollars equals 373,682,000 US dollars.
ResMed Inc. (RMD) FY2027 Q1 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Intelligent Insights for Investors

Is ResMed bringing in more cash from operations than a year ago?

No: cash from operations, the cash its everyday business brings in once its bills are paid, came to $422.42 M this quarter, $34.90 M lower than a year earlier. Over the same span, profit, what is left after every cost, interest charge and tax, plus any gains on the side, rose $69.88 M.

Did free cash cover dividends and buybacks?

No: dividends and buybacks took $1.03 B this quarter, more than the $373.68 M left after spending on property and equipment. Its cash balance fell over the same period.

Are buybacks actually reducing the share count?

The share count is falling. ResMed spent $936.38 M buying back shares this quarter, and its average diluted share count was down 2.4% from a year earlier, at 143 million shares.

Intelligent Insights for Lenders

Is ResMed borrowing more or paying down debt?

ResMed is paying debt down: repayments beat new borrowing by $250.00 M this quarter, where a year earlier it had no net borrowing. The company repaid its 3.24% senior notes in full on July 10, 2026, and had $410 M outstanding at quarter end.

Intelligent Insights for Employees

How much does ResMed pay its people in stock instead of cash?

ResMed paid its people $29.48 M in stock this quarter, equal to 2.1% of sales and 7.0% of its cash from operations. Because the pay is in shares, the expense is added back to get cash from operations.

Intelligent Insights for Suppliers

Did ResMed slow its inventory purchases from suppliers?

No: it bought more than it sold. Purchases implied by cost of sales and the change in inventory came to $619.80 M this quarter, 14% above its $544.25 M cost of sales, as inventory grew.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!